FATE - NASDAQ
Fate Therapeutics, Inc.
$2.57
-14%Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
At a Glance
Live SnapshotFate Therapeutics, Inc. Management Team
Ms. Cindy R. Tahl J.D.
Chief Legal & Compliance Officer and Corporate Secretary
Compensation
$644,600
Ms. Kate Duvall
Corporate Controller
Dr. Yu Cai
Head of Intellectual Property & Assistant General Counsel
Dr. Bahram Valamehr M.B.A., Ph.D.
President, Chief Executive Officer & Director
Compensation
$676,600
Mr. Andrew Henry
Senior Vice President of Clinical Operations
Dr. Tunde Babalola
Senior Vice President of Technical Operations
Ms. Jessica Francis
Vice President Of Human Resources & Operations
Mr. Victor Hong
Vice President of Corporate Development & Finance
Fate Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have sold $144K worth of FATE shares, with no buying activity reported.
3 Months
0
0.00
54.5K
102.56K
-103K
-$103K
3-6 Months
0
0.00
15.8K
16.83K
-17K
-$17K
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
0
0.00
23.5K
24.97K
-25K
-$25K
Top Buyers
No buying activity
Top Sellers
Valamehr Bahram
Director, Officer: President And Ceo
$75K
Tahl Cindy
Officer: See Remarks
$69K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $144K net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
2 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Persistent selling pressure: Consistent insider selling with weak buy/sell ratio suggests insiders may be capitalizing on current valuation. Exercise caution and review recent earnings quality and management commentary.
SEC Filings
FATE - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 24, 2026 | June 12, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 17, 2025 | May 29, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 26, 2024 | June 07, 2024 | 2024 | |
DEF 14A DEF 14A N/A | April 21, 2023 | April 21, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 25, 2022 | June 09, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 21, 2021 | June 02, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | March 20, 2020 | May 01, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | March 22, 2019 | May 03, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | March 16, 2018 | May 02, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | March 22, 2017 | May 02, 2017 | 2017 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.